Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library · Trial & Regulatory Tracker →

Eloralintide: what the evidence says

Name: Eloralintide
Published: 2026-10-27

At a glance

What it is: Eli Lilly's once-weekly, selective amylin-receptor agonist peptide for obesity. ^R1

What the evidence says: in a 48-week phase 2 trial (n = 263), weight fell 9% to 20% depending on dose vs 0.4% on placebo. ^{R2, R3} Lilly has started several phase 3 trials, including combinations with tirzepatide. ^{R4, R5, R6}

Biggest risks: nausea and fatigue, more common at higher starting doses. ^R2

Rating


Human Human evidence	Moderate: phase 1 ^R7; one phase 2 RCT ^R2
Animal Animal / lab evidence	Discovery and animal pharmacology ^R1
Regulatory	Investigational, not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · not named on WADA's 2026 list ^{R8, R9, R10, R11}
Established human dose	None approved. Study details lists what trials used

Evidence verdict: Weight loss in obesity: Moderate (one 48-week phase 2 RCT; phase 3 under way) · Diabetes, sleep apnea, knee pain: Pending (phase 3 trials recruiting) · Anything else: No human data

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: one 48-week phase 2 trial in US adults without diabetes; phase 3 results are expected no earlier than 2028 (trial primary completion dates). ^{R4, R5}

What is it?

Amylin is a hormone released with insulin that slows stomach emptying and signals fullness. Eloralintide is a long-acting copy aimed only at amylin receptors. ^R1 Related pages: Cagrilintide, CagriSema, Petrelintide, Pramlintide, Tirzepatide.

Does it work?

Human Phase 1, 12 weeks (n = 100): weight loss and pharmacokinetics supporting weekly dosing. ^R7
Human Phase 2, 48 weeks (n = 263): −9% (lowest dose) to −20% (highest) vs −0.4% on placebo. ^R2
Unknown Phase 3: ENLIGHTEN-1 and other trials are recruiting; no results yet. ^{R4, R5, R6}
Unknown With tirzepatide: a phase 1 study is complete with results not yet published. ^R12

Is it safe?

Human Nausea (up to 64% in one arm vs 14% placebo) and fatigue (up to 46% vs 12%). ^R2
Unknown No long-term data.

Gray-market vials: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: investigational only; not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R9, R10, R11}
Sport: not named on WADA's 2026 list. ^R8

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
Phase 1 MAD 2026	100 adults with obesity	SC weekly	5 ascending cohorts	12 weeks	Dose-proportional exposure; weight loss	PMID 41559929
Phase 2 2025	263 adults	SC weekly	1, 3, 6, 9 mg or escalations	48 weeks	−9% to −20% vs −0.4%	PMID 41207310

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 26, 2026)

^R1 Briere DA, et al. Mol Metab. 2025. PMID 41109426
^R2 Billings LK, et al. Lancet. 2025. PMID 41207310
^R3 ClinicalTrials.gov NCT06230523, Eli Lilly, phase 2 in obesity or overweight, completed May 2025, n = 263 (CT.gov API v2, checked Oct 26, 2026). https://clinicaltrials.gov/study/NCT06230523
^R4 ClinicalTrials.gov NCT07321886, Eli Lilly, ENLIGHTEN-1 phase 3 in obesity without type 2 diabetes, recruiting, n = 1,980, primary completion Mar 2028 (CT.gov API v2, checked Oct 26, 2026). https://clinicaltrials.gov/study/NCT07321886
^R5 ClinicalTrials.gov NCT07282600, Eli Lilly, phase 3 in obesity with type 2 diabetes, recruiting, n = 1,035, primary completion Jan 2028 (CT.gov API v2, checked Oct 26, 2026). https://clinicaltrials.gov/study/NCT07282600
^R6 ClinicalTrials.gov NCT07881432, Eli Lilly, phase 3 eloralintide + tirzepatide ("EloraTZP") in obesity, not yet recruiting, n = 2,115, primary completion Oct 2029 (CT.gov API v2, checked Oct 26, 2026). https://clinicaltrials.gov/study/NCT07881432
^R7 Bhattachar S, et al. Diabetes Obes Metab. 2026. PMID 41559929
^R8 WADA. The 2026 Prohibited List, full list checked; compound not named. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R9 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R10 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R11 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
^R12 ClinicalTrials.gov NCT06916065, Eli Lilly, phase 1 eloralintide alone and with tirzepatide, completed Jan 2026, n = 188 (CT.gov API v2, checked Oct 26, 2026). https://clinicaltrials.gov/study/NCT06916065

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use Eloralintide. Eloralintide is only available in clinical trials. Retail vials labeled as eloralintide are unverified products. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).